Jci_page_head_homepage_01 Jci_page_head_homepage_02
Log in
Create account or
Reset password

Subscription options
  • Purchase this article...
  • Price: $5
    Purchasing this article will give you full access for the calendar year.
  • Purchase Site Pass...
  • Price: $10
    This will give you access to every article on the site for 24 hours.
  • Online subscription...
  • Price: $95
    Individual online subscriptions give you full online access for the calendar year.
  • Print subscription...
  • Price: $250*
    Individual print subscriptions give you the print journal and full online access for the year.
    *Price outside U.S. and Canada: $475.

Continue reading with a subscription.

A subscription is required for you to read this article in full. If you are a subscriber, you may log in to continue reading.
If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).
Problems? Please try these troubleshooting tips.

Science in Medicine

Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover

Roger H. Unger, Alan D. Cherrington

Published January 3, 2012

The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor–null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.

Preview pages

Reset
Page preview
5 Page 4 Back